IRD Opus Genetics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1228627 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-45.9%
TTM net income YoY-100.4%
TTM EPS YoY20.4%
Revenue 3-yr CAGR-48.3%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-777.7%
Net margin-1,726.7%
FCF margin—
EBITDA margin-776.9%
Returns
ROE-615.6%
ROA-208.0%
ROIC (approx.)—
Asset turnover0.12x
Leverage & solvency
Liabilities / assets59.7%
Debt / equity0.93x
Current ratio9.65x
Interest coverage-217.47x
Cash quality & payout
Operating cash flow / net income0.36x
Accruals ratio-134.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $14.20M | $10.99M | $19.05M | $39.85M | $589,000 |
| R&D expense | $30.81M | $26.85M | $17.65M | $14.36M | $15.17M |
| SG&A expense | $21.98M | $18.21M | $11.96M | $7.27M | $8.12M |
| Operating income | -$38.60M | -$62.07M | -$10.56M | $18.23M | -$22.70M |
| Interest expense | $129,000 | $0 | $0 | $9,000 | $2,000 |
| Pretax income | -$49.59M | -$57.53M | -$9.97M | $18.20M | -$56.69M |
| Income tax | $0 | $0 | $12,000 | $315,000 | $0 |
| Net income | -$49.59M | -$57.53M | -$9.99M | $17.89M | -$56.69M |
| EBITDA | -$38.55M | -$62.06M | -$10.56M | $18.23M | -$22.70M |
| EPS (basic) | -0.80 | -2.15 | -0.46 | 0.90 | -3.82 |
| EPS (diluted) | -0.80 | -2.15 | -0.46 | 0.87 | -3.82 |
| Weighted avg. shares (diluted) | 62.22M | 26.72M | 21.59M | 20.60M | 14.85M |
| Balance sheet | |||||
| Cash & equivalents | $45.09M | $30.32M | $50.50M | $42.63M | $24.53M |
| Short-term investments | $0 | $2,000 | $15,000 | $49,000 | $219,000 |
| Receivables | $2.00M | $3.56M | $926,000 | $1.30M | $0 |
| Current assets | $50.04M | $36.61M | $53.95M | $48.99M | $26.07M |
| PP&E, net | $199,000 | $252,000 | $0 | $6,000 | $10,000 |
| Total assets | $50.24M | $36.86M | $53.95M | $48.99M | $26.08M |
| Current liabilities | $7.78M | $11.29M | $4.04M | $2.75M | $3.85M |
| Short-term debt | — | — | — | $0 | $538,000 |
| Long-term debt | $1.13M | $0 | — | — | — |
| Total debt | $1.13M | $0 | — | — | — |
| Total liabilities | $34.90M | $11.29M | $4.04M | $2.75M | $3.85M |
| Shareholders' equity | $15.35M | $6.72M | $49.91M | $46.24M | $22.22M |
| Net debt | -$43.96M | -$30.32M | — | — | — |
| Shares outstanding | 69.89M | 31.57M | 23.98M | 20.86M | 18.85M |
| Cash flow statement | |||||
| Operating cash flow | -$35.25M | -$25.58M | -$1.11M | $14.31M | -$19.37M |
| Investing cash flow | $0 | $1.21M | $0 | $0 | -$100,000 |
| Financing cash flow | $50.02M | $4.19M | $8.98M | $3.79M | $27.61M |
| Depreciation & amortization | $53,000 | $10,000 | $6,000 | $4,000 | $4,000 |
| Stock-based compensation | $3.40M | $3.36M | $3.51M | $1.81M | $1.91M |
Free plan shows the latest 5 periods; Pro shows all 24 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.